Conversion Disorder
Conversion disorder is a mental condition in which a person has blindness, paralysis, or other nervous system (neurologic) symptoms that cannot be explained by medical evaluation.
Cluster Number:
Wiki Number: W049
Diagnosis: Conversion Disorder
US Patients: 0.11-0.5%
World Patients:
Sex Ratio: 1M;4W
Age Onset: Ages-10-35
Brain Area: large epinephrine release
Symptoms: psychologically triggered neurological symptoms, numbness, blindness, paralysis or fits,etc.
Progression: Trauma suddenly converted by the brain into physical limitations.
Causes: serious difficulties when no physical basis can be found; usually in motor or sensory systems
Medications:
Therapies: hypnosis, psychotherapy, physical therapy, stress management, transcranial magnetic stimulation; depression may occur.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Diagnostic conversion from unipolar to bipolar affective disorder: a population-based studyby Young Tak Jo on January 22, 2022
CONCLUSION: We confirmed diagnostic conversion in some patients and identified younger age or usage of antidepressants, especially SNRI, as risk factors. Because unipolar and bipolar affective disorders show different disease courses or prognoses and have different treatment strategies, clinicians should be mindful of diagnostic conversion.
- Sirolimus-Based Immunosuppression Is Associated with Decreased Incidence of Post-Transplant Lymphoproliferative Disorder after Heart Transplantation: A Double-Center Studyby Rabea Asleh on January 21, 2022
Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid cells; thus, their use for immunosuppression after heart transplantation (HT) may reduce post-transplant lymphoproliferative disorder (PTLD) risk. This study sought to investigate whether the sirolimus (SRL)-based immunosuppression regimen is associated with a decreased risk of PTLD compared with the calcineurin inhibitor (CNI)-based regimen in HT recipients. We retrospectively analyzed 590...
- Catabolism of Hydroxyproline in Vertebrates: Physiology, Evolution, Genetic Diseases and New siRNA Approach for Treatmentby Ruth Belostotsky on January 21, 2022
Hydroxyproline is one of the most prevalent amino acids in animal proteins. It is not a genetically encoded amino acid, but, rather, it is produced by the post-translational modification of proline in collagen, and a few other proteins, by prolyl hydroxylase enzymes. Although this post-translational modification occurs in a limited number of proteins, its biological significance cannot be overestimated. Considering that hydroxyproline cannot be re-incorporated into pro-collagen during...
- Toward a Multimodal Computer-Aided Diagnostic Tool for Alzheimer's Disease Conversionby Danilo Pena on January 20, 2022
Alzheimer's disease (AD) is a progressive neurodegenerative disorder. It is one of the leading sources of morbidity and mortality in the aging population AD cardinal symptoms include memory and executive function impairment that profoundly alters a patient's ability to perform activities of daily living. People with mild cognitive impairment (MCI) exhibit many of the early clinical symptoms of patients with AD and have a high chance of converting to AD in their lifetime. Diagnostic criteria rely...